Becton, Dickinson and Company (BDX) Stock

About Becton, Dickinson and Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Becton, Dickinson and Company is led by CEO Thomas E. Polen Jr., employs 70,000 people, headquartered in Franklin Lakes, US, publicly traded since 1973.

Becton, Dickinson and Company (BDX) stock trades at $168.40 with a market capitalization of $61.01B. The stock is valued at a price-to-earnings (P/E) ratio of 26.08, price-to-book of 1.74, price-to-sales of 2.46. Over the past 52 weeks the stock has ranged between $127.59 and $187.35, and currently trades 10.1% below its 52-week high. It pays a dividend yielding 2.58%.

On profitability, Becton, Dickinson and Company generates a return on equity (ROE) of 6.67%, return on capital employed of 10.15%, an operating margin of 11.80%, a net profit margin of 5.33%.

In its most recent fiscal year, Becton, Dickinson and Company reported annual revenue of $21.8B, net profit of $1.7B, revenue has compounded at 6.3% a year over the last five years, profit at 13.9% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.72, a current ratio of 1.11, total assets of $55.3B, $851.0M in cash and equivalents.

BDX has an average daily trading volume of 2,707,280 shares, a beta of 0.28 (less volatile than the overall market).

Official website: www.bd.com